ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care
The Clinical Fellowship Program will provide funding for up to eight one-year fellowships, to established amyloidosis centers across
"This program represents a significant step forward in building a robust workforce capable of addressing the complex challenges of amyloidosis," said Dr.
Marking a commitment to future advancements in amyloidosis care, ARC's CEO,
Key Dates:
- Deadline for Center Applications:
December 15, 2024
- Committee Review Complete:
January 10, 2025
- Notification to Applicants:
January 15, 2025
- Fellow Start Date: Summer 2025
For more information on the ARC Clinical Fellowship Program and eligibility criteria, please visit arci.org/fellowship or contact
This activity is supported by an independent educational grant from Astra Zeneca and Ionis Pharmaceuticals.
About the Amyloidosis Research Consortium (ARC)
The Amyloidosis Research Consortium is dedicated to improving the understanding, diagnosis, and treatment of amyloidosis through research, education, and collaboration. ARC strives to promote advancements in patient care and foster a community of researchers and clinicians dedicated to eradicating this disease.
Amyloidosis Research Consortium Contact:
Director of Community Programs
Amyloidosis Research Consortium (ARC)
617-467-5170
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/arc-launches-clinical-fellowship-program-to-advance-amyloidosis-care-302292264.html
SOURCE AMYLOIDOSIS RESEARCH CONSORTIUM
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Frontier Technologies and MSP Hub Launch Strategic Alliance
- FINN Partners Expands U.S. Footprint with New Columbus Office, Names Marty McDonald Midwest Deputy and Member of Global Travel Leadership
- CNCF Announces Graduation of Cloud Native Buildpacks, Advancing the Standard for Container Builds
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share